DBPR807 can significantly suppress tumor growth, prevent distant metastasis, reduce angiogenesis, normalize tumor microenvironment and promote cytotoxic T-cell infiltration. In various HCC models, DBPR807 itself can prolong overall survival as effectively as marketed anti-angiogenic agent sorafenib and immune checkpoint inhibitor anti-PD-1 Ab. What’s more, its combination therapy with either sorafenib or anti-PD-1 Ab can extend life expectancy even more significantly than aforementioned monotherapy.
